On the evening of April 18, Puli Pharmaceuticals (300630.
SZ) issued an announcement stating that Zhejiang Puli Pharmaceutical Co.
, a wholly-owned subsidiary of the company, had recently received the 500mg Levofloxacin Tablets "Drug Registration Certificate" ( Category 4 generic drugs).
Levofloxacin (levofloxacin, LVLX) is the levofloxacin optical isomer of the fluoroquinolone drug ofloxacin, and its antibacterial activity in vitro is twice that of ofloxacin.
Because of its strong antibacterial effect, broad antibacterial spectrum, and a positive antibacterial effect, it is currently the first-line clinical anti-infection drug.
It can be used to treat adult (≥18 years old) infections caused by designated susceptible bacteria.
Levofloxacin was developed by Daiichi Pharmaceutical (Daiichi Sankyo Co.
) and has been listed in more than 40 countries around the world.
In China, the Daiichi Sankyo Pharmaceutical (Beijing) Co.
's levofloxacin tablets have been approved, the trade name is Kolabit, and the specifications: 0.
1g and 0.
Zhejiang Puli's levofloxacin tablets have been submitted for registration in the European Union (Netherlands and Germany) and China after the start of research and development.
They are co-production products and have been included in the priority review category.
Among them, another specification of 250mg developed in the same period has also obtained the "Drug Registration Certificate" issued by the State Drug Administration in February 2021, and has successfully entered the national drug collection catalog.